Neoadjuvant ddMVAC (bladder) & Nivo + Chemo (NSCLC)
Mar 10, 2022
17:10
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Results from VESPER are now published, so we revisit neoadjuvant ddMVAC and its place as SOC in bladder cancer. Nivolumab nets a new approval with chemo for neoadjuvant treatment of NSCLC. A new CAR-T product is approved for multiple myeloma.
